Specialty Pharmacy

Drug-carrying synthetic polymer could deliver treatment to lung cancer cells without harming healthy cells.

Positive data from a pair of clinical trials announced at the 25th European Academy of Dermatology and Venereology Congress show Dupixent (dupilumab) is an effective option for moderate-to-severe atopic dermatitis.

Research presented at the 25th European Academy of Dermatology and Venereology Congress focused on the effects of crisaborole topical ointment in treating atopic dermatitis.

Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.

New data for dupilumab presented at the 25th European Academy of Dermatology and Venereology Congress.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed effective techniques to boost HIV drug adherence.

Top news of the week in cancer research.

The promise of sentinel lymph node biopsies for melanoma highlighted at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria.

Immune checkpoint inhibitors could improve malignant melanoma therapy, according to a study presented at the Congress of the European Academy of Dermatology and Venerology.

Whether or not cancer cells remain in a cancer patient while undergoing treatment may effect multiple myeloma survival.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed the importance of persistence in Truvada use for HIV pre-exposure prophylaxis.

Adherence programs needed to boost Xeljanz utilization for rheumatoid arthritis.

Top articles of the week on Specialty Pharmacy Times.

DHODH inhibitor caused a reduction in leukemic stem cells and long-term remission in mice.

AbbVie’s experimental compound treats moderate-to-severe chronic plaque psoriasis.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed hurdles to proper drug adherence in HIV treatment.

Researchers create a treatment approach that singles out HIV reservoirs.

Top news of the day from across the health care landscape.

A new biomarker reveals how the disease will progress in patients.

Clinical trial presented at the 25th Annual European Academy of Dermatology and Venereology Congress found a new topical allantoin cream can help treat epidermolysis bullosa.

Using precision medicine, researchers were able to slow down the amount of time it takes for a tumor to grow back in patients with advanced cancer.

Stephen I. Katz, MD, PhD, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, kicked off the European Academy of Dermatology and Venereology Congress highlighting the future of dermatology treatment.

Data presented at the European Academy of Dermatology and Venereology (EADV) Annual Congress shows safety and efficacy of apremilast (Otezla) over three years.

Aleksandar L. Krunic, MD, PhD, discusses tumor removal in Mohs disease during the 25th European Academy of Dermatology and Venereology Congress.

For the first time, researchers have identified the presence of fungi in the intestines that are a key factor in the disease.

Tumor cells grown in mice first could potentially change the cancer research landscape.

Top news of the day from across the health care landscape.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses challenges balancing the quality of care with the high cost of treatments.

Patients risk the development of thyroid dysfunction from interferon alpha in patients with hepatitis C virus infection.

Aleksandar L. Krunic, MD, PhD, discusses treatment strategies for rare tumor types in Mohs disease during the 25th European Academy of Dermatology and Venereology Congress.